|
SMi is proud to present their 3rd annual conference on Biomarkers in Clinical Trials. With the 2011 event aiming to explore the use of biomarkers in Cancer drug development.
Concerns over efficacy, cost, and drug safety have stimulated a need for personalized medicine; and to increase the predictability of clinical research to reduce development cost and time. The use of biomarkers in no longer limited to whether a patient will respond to a treatment, but has extended to aid drug development in all its forms.
As a result biomarkers have now gained significant attention in the R&D process. Which are seen as an emerging but lucrative segment that is opening up new development opportunities, and attracting much commercial interest.
The global biomarker market is estimated to be £12.7 billion by 2014, and driven by the high demand for the biomarkers in the field of drug discovery.
In addition the increasing use of biomarkers in clinical services is boosting the overall biomarker service provider market.
"Over 10 million new cancer cases will be diagnosed worldwide over the next year and there is an unmet need for effective, less toxic cancer therapeutics. Our rapidly expanding understanding of how cellular immortality contributes to cancer progression offers an opportunity for the exploitation of the underlying molecular mechanisms into safe and effective new therapies."
Nicol Keith, Professor of Molecular Oncology, Centre for Oncology & Applied Pharmacology
Interested in speaking at the conference?
We are always on the look-out for new speakers and interested projects for our upcoming conferences. Let us know if you would like to participate by emailing smiproduction@smi-online.co.uk
For event sponsorship and exhibiting opportunities, please contact sponsorshipdept@smi-online.co.uk
 |
|
What our previous delegates had to say
“Good relevant content, very well chaired, good presentations”
Group Leader, UCB
“It was very interesting for me as I have recently moved from translational research to more clinical – translational and diagnostic research. There was a good overview of the field of biomarkers in clinical trials.”
Scientific Co-ordinator for Molecular Pathology, UCL Cancer Institute
"Great mix of Pharma and Non-Pharma"
Biomarker Logistics Manager, Merck Serono
|
|
Events Home Page
